Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antifungal medication

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Antifungal medication. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-002644-23 Sponsor Protocol Number: MB_PDT_1 Start Date*: 2020-07-23
    Sponsor Name:Dept. of Dermatology, Zealand University Hospital, Roskilde
    Full Title: Photodynamic therapy of antifungal resistant dermatophytes
    Medical condition: Competent patients over 18 years old with mycological verified antifungal resistant dermatophytosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10043870 Tinea infections HLT
    20.0 10021881 - Infections and infestations 10043868 Tinea cruris PT
    20.0 10021881 - Infections and infestations 10060889 Tinea infection PT
    21.1 10021881 - Infections and infestations 10043873 Tinea pedis PT
    20.0 10021881 - Infections and infestations 10049591 Tinea imbricata PT
    20.0 10021881 - Infections and infestations 10067197 Tinea manuum PT
    20.0 10021881 - Infections and infestations 10043872 Tinea NOS LLT
    20.1 10021881 - Infections and infestations 10043869 Tinea infection NOS LLT
    20.0 10021881 - Infections and infestations 10043867 Tinea corporis LLT
    20.0 10021881 - Infections and infestations 10043864 Tinea LLT
    20.0 10021881 - Infections and infestations 10053041 Tinea trichophytina cruris LLT
    20.0 10021881 - Infections and infestations 10073383 Tinea of hand LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001585-15 Sponsor Protocol Number: 2018-01671 Start Date*: 2020-01-30
    Sponsor Name:Centre Hospitalier Universitaire Vaudois
    Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia
    Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000381-29 Sponsor Protocol Number: SCY-078-301 Start Date*: 2017-07-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to, Resistant to or Intolerant of Standard Antifungal Treatment (FURI)
    Medical condition: Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-002204-38 Sponsor Protocol Number: NDI-2020 Start Date*: 2020-11-24
    Sponsor Name:Claus Bistrup
    Full Title: Treatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication
    Medical condition: Nephrogenic diabetes insipidus
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10012600 Diabetes insipidus nephrogenic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001194-29 Sponsor Protocol Number: OSHO #075 Start Date*: 2008-01-11
    Sponsor Name:Universität Leipzig
    Full Title: An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy
    Medical condition: Patients with acute myeloid leukemia not eligible for or resistant to chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003140-68 Sponsor Protocol Number: MK5592-105-00 Start Date*: 2012-10-29
    Sponsor Name:MSD
    Full Title: A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients
    Medical condition: Invasive fungal infection (IFI) in lung transplant patients with and without cystic fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10042613 - Surgical and medical procedures 10049085 Antifungal prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001472-22 Sponsor Protocol Number: IMUNOR-201501 Start Date*: 2017-03-14
    Sponsor Name:ImunomedicA, a.s.
    Full Title: A Prospective, Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Study Assessing Efficacy and Safety of the IMUNOR® Therapy Versus Placebo in Patients with Recurrent Vulvovaginit...
    Medical condition: Recurrent vulvovaginitis episodes
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10047794 Vulvovaginitis PT
    Population Age: Adults Gender: Female
    Trial protocol: SK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001491-39 Sponsor Protocol Number: 03-0-192 Start Date*: 2005-02-16
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA
    Medical condition: Invasive candidiasis or candidemia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10042938 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) BE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002565-18 Sponsor Protocol Number: SCY-078-206 Start Date*: 2019-10-04
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 with Voriconazole in Patients with Invasive Pulmonary Aspergillosis (SCYNERGIA)
    Medical condition: Patients with Invasive Pulmonary Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001916-41 Sponsor Protocol Number: C11-11 Start Date*: 2014-11-24
    Sponsor Name:Inserm
    Full Title: Fluconazole versus Micafungin in neonates with suspected or culture-proven Candidiasis: a randomized pharmacokinetic and safety study
    Medical condition: Neonates with suspected or culture-proven candidiasis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003148-31 Sponsor Protocol Number: P05115 Start Date*: 2007-10-12
    Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation
    Full Title: A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole Among Patients with Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection.
    Medical condition: Acute Myeloid Leukemia, Neutropenia, Antifungal Prophylaxis, Gastrointestinal Disorders
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    9.1 10029354 Neutropenia LLT
    9.1 10049085 Antifungal prophylaxis LLT
    9.1 10017948 Gastrointestinal disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002587-28 Sponsor Protocol Number: 2019-5165 Start Date*: 2020-02-25
    Sponsor Name:Radboudumc
    Full Title: ABSORB 2:An exploratie study determining the oral antibiotic drug absorption in patients with short bowel syndrome.
    Medical condition: short bowel syndrome, home parenteral nutrition
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012848-16 Sponsor Protocol Number: A1501085 Start Date*: 2010-04-28
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
    Full Title: A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPH...
    Medical condition: Invasive candidiasis, including candidemia (ICC), and esophageal candidiasis (EC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10060573 Candidemia LLT
    14.1 10021881 - Infections and infestations 10064954 Invasive candidiasis LLT
    14.1 10021881 - Infections and infestations 10007161 Candidiasis of the esophagus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) BG (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003087-70 Sponsor Protocol Number: PM1125 Start Date*: 2011-12-02
    Sponsor Name:Polichem SA
    Full Title: Randomized, open-label, controlled study on the efficacy of Ciclopoli® (ciclopirox 8% nail lacquer) versus Loceryl® (amorolfine 5% nail lacquer) on the culture conversion to negative in patients w...
    Medical condition: distal subungual onychomycosis without lunula involvement due to fungal nail pathogens (dermatophytes, white yeasts and/or Scopulariopsis spp. and/or Fusarium spp.) affecting at least one big toenail
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-002600-40 Sponsor Protocol Number: SCY-078-304 Start Date*: 2020-01-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects with Recurrent Vulvova...
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-000780-24 Sponsor Protocol Number: 9463-CL-2303 Start Date*: 2012-07-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis
    Medical condition: Neonatal Candidiasis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-000386-32 Sponsor Protocol Number: F901318/0041 Start Date*: 2022-01-21
    Sponsor Name:F2G Ltd.
    Full Title: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with...
    Medical condition: invasive fungal infections due to Aspergillus spp.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000244-26 Sponsor Protocol Number: PC-ASP-004 Start Date*: 2018-08-21
    Sponsor Name:Pulmocide Ltd
    Full Title: A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus or Candida fungal bronchitis in subjects with moderate to severe ast...
    Medical condition: Pulmonary aspergillosis and candidiasis of lung
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    20.0 100000004862 10007155 Candidiasis of lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001223-31 Sponsor Protocol Number: KAISII Start Date*: 2016-10-11
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis
    Medical condition: Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038271 Refractory anaemia with excess blasts in transformation LLT
    19.0 10042613 - Surgical and medical procedures 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    19.0 10042613 - Surgical and medical procedures 10067862 Allogeneic stem cell transplantation LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038270 Refractory anaemia with an excess of blasts PT
    19.0 10005329 - Blood and lymphatic system disorders 10010776 Constitutional aplastic anaemia LLT
    19.0 10005329 - Blood and lymphatic system disorders 10068063 Aplastic anaemia relapse LLT
    19.0 10005329 - Blood and lymphatic system disorders 10036699 Primary idiopathic aplastic anaemia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    19.0 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000884 Acute myeloid leukaemia NOS LLT
    19.0 10005329 - Blood and lymphatic system disorders 10032510 Other specified aplastic anaemias LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066355 Treatment related acute myeloid leukaemia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060355 Acute myeloid leukaemia in remission LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066764 Acute myeloid leukaemia progression LLT
    19.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000728-41 Sponsor Protocol Number: 06/02-29 jan'07 Start Date*: 2008-09-12
    Sponsor Name:Maastro clinic
    Full Title: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy in patients with locally advanced rectal cancer
    Medical condition: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy with locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038050 Rectal cancer stage III PT
    9.1 10038051 Rectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 07:09:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA